AM 490
Alternative Names: AM-490; Nimvec™ AM 490Latest Information Update: 06 May 2024
At a glance
- Originator Amarna Therapeutics
- Class Antihaemorrhagics; Gene therapies
- Mechanism of Action Factor IX replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haemophilia B
Most Recent Events
- 18 Apr 2024 AM 490 is available for licensing as of 18 Apr 2024. https://www.amarnatherapeutics.com/partners.html
- 12 Apr 2024 Preclinical trials in Haemophilia B in Netherlands (Parenteral), prior to April 2024 (Amarna Therapeutics pipeline, April 2024)